Compare · ARGX vs SCLX
ARGX vs SCLX
Side-by-side comparison of argenx SE (ARGX) and Scilex Holding Company (SCLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and SCLX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $55.45B, about 768.3x SCLX ($72.2M).
- Over the past year, ARGX is up 52.3% and SCLX is up 64.1% - SCLX leads by 11.8 points.
- SCLX has been more active in the news (7 items in the past 4 weeks vs 5 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 6 for SCLX).
- Company
- argenx SE
- Scilex Holding Company
- Price
- $893.38-0.46%
- $8.50-3.19%
- Market cap
- $55.45B
- $72.2M
- 1M return
- +11.31%
- +28.21%
- 1Y return
- +52.27%
- +64.09%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 5
- 7
- Recent ratings
- 25
- 6
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
- SEC Form 6-K filed by argenx SE
- argenx Reports First Quarter 2026 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2026 Health Care Conference
Latest SCLX
- Scilex Holding Company ("Scilex") Confirms the Previously Announced Payment Date of June 15, 2026 for the Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
- SEC Form EFFECT filed by Scilex Holding Company
- Scilex Holding Company ("Scilex") Announces a Payment Date of June 15, 2026 for the Previously Announced Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities
- SEC Form S-3 filed by Scilex Holding Company
- SEC Form EFFECT filed by Scilex Holding Company
- Scilex Holding Company ("Scilex") Announces Its Board of Directors Approved a Dividend of Semnur Pharmaceuticals, Inc. Common Stock to Holders of Scilex Common Stock and other Eligible Equity Securities with a Record Date of June 1, 2026
- SEC Form 10-Q filed by Scilex Holding Company
- SEC Form NT 10-Q filed by Scilex Holding Company
- Scilex Holding Company filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Scilex Holding Company